 Shanta Zimmer
Concepts (293)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 13 | 2021 | 601 | 1.180 |
Why?
| | Influenza A Virus, H1N1 Subtype | 8 | 2011 | 146 | 1.000 |
Why?
| | Physician-Patient Relations | 3 | 2016 | 537 | 0.730 |
Why?
| | Physicians, Women | 1 | 2020 | 70 | 0.650 |
Why?
| | Coronavirus Infections | 2 | 2023 | 335 | 0.620 |
Why?
| | Vulnerable Populations | 1 | 2020 | 158 | 0.620 |
Why?
| | Communicable Diseases | 1 | 2020 | 147 | 0.600 |
Why?
| | Neisseria meningitidis | 3 | 2007 | 23 | 0.590 |
Why?
| | Lymphocyte Antigen 96 | 3 | 2008 | 24 | 0.590 |
Why?
| | Internship and Residency | 6 | 2019 | 1052 | 0.560 |
Why?
| | Professional Misconduct | 1 | 2016 | 11 | 0.510 |
Why?
| | Pennsylvania | 8 | 2021 | 108 | 0.490 |
Why?
| | Meningitis, Meningococcal | 2 | 2006 | 6 | 0.490 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 341 | 0.480 |
Why?
| | Faculty | 1 | 2016 | 137 | 0.480 |
Why?
| | Curriculum | 4 | 2024 | 916 | 0.470 |
Why?
| | Meningococcal Vaccines | 2 | 2006 | 54 | 0.470 |
Why?
| | Internal Medicine | 4 | 2018 | 248 | 0.440 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 156 | 0.380 |
Why?
| | Influenza Vaccines | 6 | 2011 | 532 | 0.370 |
Why?
| | Physicians | 3 | 2016 | 864 | 0.360 |
Why?
| | Education, Medical, Graduate | 4 | 2019 | 437 | 0.350 |
Why?
| | Computer Simulation | 9 | 2012 | 943 | 0.330 |
Why?
| | Education, Medical, Undergraduate | 1 | 2012 | 176 | 0.330 |
Why?
| | Students, Medical | 2 | 2024 | 315 | 0.330 |
Why?
| | Toll-Like Receptor 4 | 4 | 2008 | 263 | 0.330 |
Why?
| | Reassortant Viruses | 1 | 2009 | 7 | 0.320 |
Why?
| | Zoonoses | 1 | 2009 | 29 | 0.310 |
Why?
| | Communicable Diseases, Emerging | 1 | 2009 | 33 | 0.310 |
Why?
| | Orthomyxoviridae Infections | 1 | 2009 | 67 | 0.310 |
Why?
| | Lipid A | 3 | 2007 | 29 | 0.300 |
Why?
| | Respiratory Tract Infections | 2 | 2023 | 376 | 0.280 |
Why?
| | Zygomycosis | 1 | 2007 | 6 | 0.280 |
Why?
| | Cyclosporiasis | 1 | 2007 | 1 | 0.280 |
Why?
| | Paclitaxel | 1 | 2008 | 217 | 0.270 |
Why?
| | Dermatomycoses | 1 | 2007 | 7 | 0.270 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2008 | 187 | 0.270 |
Why?
| | Sexual and Gender Minorities | 2 | 2022 | 194 | 0.270 |
Why?
| | Oxazolidinones | 2 | 2004 | 14 | 0.270 |
Why?
| | Acetamides | 2 | 2004 | 36 | 0.260 |
Why?
| | Thiazoles | 1 | 2007 | 117 | 0.260 |
Why?
| | Gram-Positive Bacterial Infections | 2 | 2005 | 67 | 0.260 |
Why?
| | Humans | 50 | 2024 | 129622 | 0.250 |
Why?
| | Leadership | 2 | 2020 | 354 | 0.250 |
Why?
| | Drug Hypersensitivity | 1 | 2007 | 81 | 0.250 |
Why?
| | Fungi | 1 | 2007 | 136 | 0.250 |
Why?
| | Triazoles | 1 | 2007 | 152 | 0.240 |
Why?
| | History, 21st Century | 2 | 2020 | 183 | 0.240 |
Why?
| | Schools | 4 | 2021 | 437 | 0.240 |
Why?
| | Disease Outbreaks | 5 | 2010 | 349 | 0.230 |
Why?
| | History, 20th Century | 2 | 2020 | 291 | 0.230 |
Why?
| | Exploratory Behavior | 1 | 2024 | 89 | 0.220 |
Why?
| | Medical Tourism | 1 | 2023 | 9 | 0.210 |
Why?
| | Coronavirus NL63, Human | 1 | 2023 | 3 | 0.210 |
Why?
| | Coronavirus OC43, Human | 1 | 2023 | 5 | 0.210 |
Why?
| | Coronavirus 229E, Human | 1 | 2023 | 6 | 0.210 |
Why?
| | Enterococcus faecalis | 1 | 2003 | 27 | 0.210 |
Why?
| | Models, Molecular | 1 | 2008 | 1492 | 0.210 |
Why?
| | Sulfonamides | 1 | 2007 | 496 | 0.210 |
Why?
| | Endocarditis, Bacterial | 1 | 2003 | 42 | 0.200 |
Why?
| | Clinical Clerkship | 1 | 2024 | 95 | 0.200 |
Why?
| | Models, Economic | 3 | 2012 | 53 | 0.190 |
Why?
| | Meningitis | 1 | 2023 | 80 | 0.190 |
Why?
| | Viruses | 1 | 2023 | 100 | 0.190 |
Why?
| | Pre-Exposure Prophylaxis | 2 | 2022 | 203 | 0.190 |
Why?
| | Mycobacterium abscessus | 1 | 2023 | 107 | 0.190 |
Why?
| | Emergency Responders | 1 | 2021 | 35 | 0.170 |
Why?
| | Program Evaluation | 3 | 2019 | 875 | 0.170 |
Why?
| | Crowding | 1 | 2020 | 35 | 0.170 |
Why?
| | Awards and Prizes | 1 | 2020 | 63 | 0.160 |
Why?
| | Shoulder | 1 | 2020 | 86 | 0.160 |
Why?
| | Frail Elderly | 1 | 2020 | 121 | 0.160 |
Why?
| | Prisons | 1 | 2020 | 79 | 0.160 |
Why?
| | Surgery Department, Hospital | 1 | 2018 | 20 | 0.150 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2023 | 352 | 0.150 |
Why?
| | Adult | 18 | 2023 | 35572 | 0.150 |
Why?
| | Minority Groups | 1 | 2020 | 249 | 0.150 |
Why?
| | Financing, Organized | 1 | 2018 | 30 | 0.150 |
Why?
| | Virus Diseases | 1 | 2021 | 211 | 0.150 |
Why?
| | Nursing Homes | 1 | 2020 | 159 | 0.150 |
Why?
| | Evidence-Based Medicine | 2 | 2024 | 718 | 0.150 |
Why?
| | Anesthesiology | 1 | 2018 | 45 | 0.150 |
Why?
| | Faculty, Medical | 2 | 2018 | 264 | 0.140 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2018 | 123 | 0.140 |
Why?
| | Point-of-Care Systems | 2 | 2017 | 147 | 0.140 |
Why?
| | Clinical Competence | 3 | 2024 | 1016 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 249 | 0.140 |
Why?
| | Preceptorship | 1 | 2017 | 65 | 0.140 |
Why?
| | Urban Population | 1 | 2020 | 441 | 0.140 |
Why?
| | Population Surveillance | 2 | 2011 | 439 | 0.130 |
Why?
| | Occupational Exposure | 1 | 2020 | 299 | 0.130 |
Why?
| | Societies, Medical | 1 | 2020 | 751 | 0.130 |
Why?
| | Rural Population | 1 | 2020 | 518 | 0.130 |
Why?
| | HIV Infections | 2 | 2022 | 2720 | 0.120 |
Why?
| | Female | 18 | 2022 | 68770 | 0.120 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 273 | 0.120 |
Why?
| | Endotoxins | 2 | 2007 | 220 | 0.120 |
Why?
| | Anti-HIV Agents | 1 | 2022 | 754 | 0.120 |
Why?
| | Continuity of Patient Care | 1 | 2017 | 275 | 0.120 |
Why?
| | Cardiology | 1 | 2017 | 261 | 0.120 |
Why?
| | United States | 7 | 2020 | 13900 | 0.120 |
Why?
| | Sexual Behavior | 1 | 2019 | 483 | 0.120 |
Why?
| | Antiviral Agents | 2 | 2011 | 712 | 0.120 |
Why?
| | Binding Sites | 2 | 2008 | 1252 | 0.110 |
Why?
| | Recombinant Proteins | 2 | 2008 | 1304 | 0.110 |
Why?
| | Male | 17 | 2022 | 63674 | 0.110 |
Why?
| | Hand Hygiene | 1 | 2013 | 8 | 0.110 |
Why?
| | Work Schedule Tolerance | 1 | 2013 | 42 | 0.110 |
Why?
| | Macrophage Activation | 2 | 2005 | 189 | 0.110 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2013 | 89 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2003 | 1717 | 0.100 |
Why?
| | Macrophages | 4 | 2008 | 1480 | 0.100 |
Why?
| | Receptors, Cell Surface | 2 | 2005 | 380 | 0.100 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2011 | 2073 | 0.100 |
Why?
| | Patient Admission | 1 | 2013 | 182 | 0.100 |
Why?
| | Membrane Glycoproteins | 2 | 2005 | 474 | 0.100 |
Why?
| | Social Support | 1 | 2016 | 588 | 0.090 |
Why?
| | Surveys and Questionnaires | 3 | 2021 | 5401 | 0.090 |
Why?
| | Patients | 1 | 2013 | 167 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1486 | 0.090 |
Why?
| | Aged | 8 | 2020 | 22099 | 0.090 |
Why?
| | Antibodies, Viral | 2 | 2021 | 601 | 0.090 |
Why?
| | Poverty Areas | 1 | 2011 | 35 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 2 | 2011 | 2282 | 0.090 |
Why?
| | Health Care Costs | 2 | 2011 | 367 | 0.090 |
Why?
| | Patient Preference | 1 | 2013 | 185 | 0.090 |
Why?
| | Guanidines | 1 | 2011 | 36 | 0.090 |
Why?
| | Hospitalization | 1 | 2020 | 2070 | 0.090 |
Why?
| | Cyclopentanes | 1 | 2011 | 19 | 0.090 |
Why?
| | Quality Improvement | 1 | 2019 | 1101 | 0.090 |
Why?
| | Hemagglutinins | 1 | 2010 | 9 | 0.090 |
Why?
| | Students | 1 | 2016 | 580 | 0.090 |
Why?
| | Clostridium Infections | 1 | 2011 | 64 | 0.090 |
Why?
| | Pneumococcal Infections | 1 | 2011 | 110 | 0.080 |
Why?
| | Communication | 1 | 2016 | 846 | 0.080 |
Why?
| | Quarantine | 1 | 2010 | 27 | 0.080 |
Why?
| | Health Care Rationing | 1 | 2010 | 57 | 0.080 |
Why?
| | Occupational Health Services | 1 | 2009 | 31 | 0.080 |
Why?
| | Influenza A Virus, H2N2 Subtype | 1 | 2009 | 1 | 0.080 |
Why?
| | Seasons | 2 | 2023 | 502 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 221 | 0.080 |
Why?
| | Antigenic Variation | 1 | 2009 | 10 | 0.080 |
Why?
| | Staphylococcal Infections | 2 | 2012 | 393 | 0.080 |
Why?
| | Young Adult | 7 | 2020 | 12426 | 0.080 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 221 | 0.080 |
Why?
| | Cross Infection | 1 | 2011 | 218 | 0.080 |
Why?
| | Antibody Specificity | 1 | 2009 | 184 | 0.080 |
Why?
| | Birds | 1 | 2009 | 83 | 0.080 |
Why?
| | Child | 9 | 2023 | 20882 | 0.080 |
Why?
| | Genome, Viral | 1 | 2009 | 129 | 0.080 |
Why?
| | Primary Prevention | 1 | 2010 | 188 | 0.070 |
Why?
| | Disease Management | 1 | 2012 | 589 | 0.070 |
Why?
| | Child, Preschool | 7 | 2021 | 10518 | 0.070 |
Why?
| | Meningitis, Bacterial | 1 | 2008 | 48 | 0.070 |
Why?
| | Carbohydrate Conformation | 1 | 2007 | 15 | 0.070 |
Why?
| | Pichia | 1 | 2007 | 22 | 0.070 |
Why?
| | Protein Structure, Secondary | 1 | 2008 | 341 | 0.070 |
Why?
| | Cell Line | 3 | 2008 | 2781 | 0.070 |
Why?
| | Cyclospora | 1 | 2007 | 1 | 0.070 |
Why?
| | Asthma | 1 | 2020 | 2230 | 0.070 |
Why?
| | Antiparasitic Agents | 1 | 2007 | 3 | 0.070 |
Why?
| | Nitro Compounds | 1 | 2007 | 6 | 0.070 |
Why?
| | Surface Properties | 1 | 2008 | 399 | 0.070 |
Why?
| | Tubulin | 1 | 2008 | 137 | 0.070 |
Why?
| | Species Specificity | 1 | 2008 | 575 | 0.070 |
Why?
| | Linezolid | 2 | 2004 | 20 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2011 | 423 | 0.070 |
Why?
| | Swine | 1 | 2009 | 760 | 0.070 |
Why?
| | District of Columbia | 3 | 2011 | 26 | 0.070 |
Why?
| | Neonatal Screening | 1 | 2008 | 163 | 0.070 |
Why?
| | Phylogeny | 1 | 2010 | 852 | 0.070 |
Why?
| | Antifungal Agents | 1 | 2007 | 129 | 0.060 |
Why?
| | Chronic Disease | 1 | 2012 | 1720 | 0.060 |
Why?
| | Protein Structure, Tertiary | 1 | 2008 | 840 | 0.060 |
Why?
| | Adolescent | 7 | 2022 | 20391 | 0.060 |
Why?
| | Vancomycin Resistance | 1 | 2005 | 14 | 0.060 |
Why?
| | Enterococcus | 1 | 2005 | 25 | 0.060 |
Why?
| | Evolution, Molecular | 1 | 2009 | 466 | 0.060 |
Why?
| | Antigens, Differentiation | 1 | 2005 | 81 | 0.060 |
Why?
| | Transfection | 1 | 2007 | 911 | 0.060 |
Why?
| | Efficiency | 2 | 2019 | 91 | 0.060 |
Why?
| | Middle Aged | 9 | 2021 | 31150 | 0.060 |
Why?
| | Health Services Accessibility | 1 | 2011 | 902 | 0.050 |
Why?
| | Vaccines, Conjugate | 1 | 2004 | 63 | 0.050 |
Why?
| | Receptors, Immunologic | 1 | 2005 | 216 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2008 | 2012 | 0.050 |
Why?
| | Lipopolysaccharides | 2 | 2005 | 875 | 0.050 |
Why?
| | Animals | 5 | 2009 | 35360 | 0.050 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2004 | 87 | 0.050 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2004 | 126 | 0.050 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2008 | 1198 | 0.050 |
Why?
| | Aged, 80 and over | 4 | 2020 | 7084 | 0.050 |
Why?
| | Bacteremia | 1 | 2005 | 197 | 0.050 |
Why?
| | Models, Statistical | 3 | 2011 | 623 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2832 | 0.050 |
Why?
| | Odds Ratio | 2 | 2021 | 1023 | 0.050 |
Why?
| | Protein Binding | 1 | 2008 | 2121 | 0.050 |
Why?
| | Anti-Infective Agents | 1 | 2004 | 248 | 0.050 |
Why?
| | Infant | 4 | 2012 | 9025 | 0.050 |
Why?
| | Influenza B virus | 1 | 2021 | 37 | 0.050 |
Why?
| | Contact Tracing | 1 | 2021 | 23 | 0.040 |
Why?
| | Monte Carlo Method | 2 | 2011 | 143 | 0.040 |
Why?
| | Absenteeism | 1 | 2021 | 47 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2022 | 175 | 0.040 |
Why?
| | Membrane Cofactor Protein | 2 | 2011 | 13 | 0.040 |
Why?
| | Risk Factors | 3 | 2021 | 9763 | 0.040 |
Why?
| | Learning | 1 | 2024 | 402 | 0.040 |
Why?
| | Ecology | 1 | 2021 | 108 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2007 | 4083 | 0.040 |
Why?
| | Stem Cells | 1 | 2023 | 577 | 0.040 |
Why?
| | Diabetes Mellitus | 1 | 2007 | 1001 | 0.040 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 239 | 0.040 |
Why?
| | Regression Analysis | 1 | 2021 | 993 | 0.040 |
Why?
| | Cost-Benefit Analysis | 2 | 2011 | 569 | 0.040 |
Why?
| | Temperature | 1 | 2021 | 636 | 0.040 |
Why?
| | Schools, Medical | 1 | 2019 | 131 | 0.040 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 1038 | 0.040 |
Why?
| | Feedback | 1 | 2018 | 162 | 0.030 |
Why?
| | Models, Educational | 1 | 2017 | 88 | 0.030 |
Why?
| | Diagnostic Errors | 1 | 2018 | 162 | 0.030 |
Why?
| | Medication Adherence | 1 | 2022 | 558 | 0.030 |
Why?
| | Cohort Studies | 2 | 2021 | 5420 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2021 | 847 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2020 | 613 | 0.030 |
Why?
| | Mice | 3 | 2008 | 16937 | 0.030 |
Why?
| | Educational Measurement | 1 | 2018 | 262 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2020 | 738 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 1988 | 0.030 |
Why?
| | Focus Groups | 1 | 2018 | 453 | 0.030 |
Why?
| | Infant, Newborn | 3 | 2012 | 5762 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 302 | 0.030 |
Why?
| | Toll-Like Receptors | 2 | 2005 | 179 | 0.030 |
Why?
| | Age Factors | 1 | 2021 | 3144 | 0.030 |
Why?
| | Biomedical Research | 1 | 2019 | 638 | 0.030 |
Why?
| | Sex Factors | 1 | 2018 | 1968 | 0.020 |
Why?
| | Body Mass Index | 1 | 2020 | 2273 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2017 | 733 | 0.020 |
Why?
| | Signal Transduction | 1 | 2005 | 4925 | 0.020 |
Why?
| | Receptors, Interleukin-1 Type I | 1 | 2011 | 24 | 0.020 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2011 | 35 | 0.020 |
Why?
| | Acids, Carbocyclic | 1 | 2011 | 2 | 0.020 |
Why?
| | Decision Trees | 1 | 2011 | 90 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4420 | 0.020 |
Why?
| | Stochastic Processes | 1 | 2011 | 67 | 0.020 |
Why?
| | Data Collection | 1 | 2013 | 650 | 0.020 |
Why?
| | Quality-Adjusted Life Years | 1 | 2011 | 106 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2012 | 161 | 0.020 |
Why?
| | Diarrhea | 1 | 2011 | 180 | 0.020 |
Why?
| | Gene Frequency | 1 | 2011 | 503 | 0.020 |
Why?
| | Cost of Illness | 1 | 2012 | 278 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2011 | 317 | 0.020 |
Why?
| | Mass Vaccination | 1 | 2009 | 16 | 0.020 |
Why?
| | Calibration | 1 | 2010 | 140 | 0.020 |
Why?
| | Attitude to Health | 1 | 2013 | 431 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 399 | 0.020 |
Why?
| | Streptococcus pneumoniae | 1 | 2011 | 159 | 0.020 |
Why?
| | Travel | 1 | 2010 | 122 | 0.020 |
Why?
| | Immunization Programs | 1 | 2011 | 214 | 0.020 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 133 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1279 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2022 | 14519 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2011 | 352 | 0.020 |
Why?
| | Workplace | 1 | 2009 | 246 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2010 | 328 | 0.020 |
Why?
| | Occupational Health | 1 | 2009 | 192 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 2011 | 396 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2011 | 1214 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1839 | 0.020 |
Why?
| | Pilot Projects | 1 | 2011 | 1587 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2010 | 463 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2011 | 547 | 0.020 |
Why?
| | Gram-Negative Bacteria | 1 | 2005 | 70 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2005 | 273 | 0.010 |
Why?
| | DNA | 1 | 2011 | 1400 | 0.010 |
Why?
| | Incidence | 1 | 2011 | 2644 | 0.010 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2005 | 96 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2008 | 867 | 0.010 |
Why?
| | Growth | 1 | 2004 | 58 | 0.010 |
Why?
| | Respiratory Burst | 1 | 2004 | 15 | 0.010 |
Why?
| | U937 Cells | 1 | 2004 | 24 | 0.010 |
Why?
| | Sugar Acids | 1 | 2004 | 4 | 0.010 |
Why?
| | Antigens, Surface | 1 | 2004 | 151 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1722 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2017 | 10226 | 0.010 |
Why?
| | Toll-Like Receptor 2 | 1 | 2004 | 113 | 0.010 |
Why?
| | Vaccination | 1 | 2011 | 1348 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2004 | 548 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 5066 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2005 | 399 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2008 | 3381 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2005 | 902 | 0.010 |
Why?
| | Time Factors | 1 | 2009 | 6556 | 0.010 |
Why?
| | Cytokines | 1 | 2005 | 2017 | 0.010 |
Why?
|
|
Zimmer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|